Valacyclovir v placebo for symptomatic genital herpes simplex virus type 2 (HSV-2) infection*
| Outcomes at 8 months | Valacyclovir | Placebo | Hazard ratio (95% CI) | NNT (CI) |
|---|---|---|---|---|
| *Abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article. | ||||
| Symptomatic HSV-2 infection in HSV-2 seronegative partners | 0.5% | 2.2% | 0.25 (0.08 to 0.75) | 62 (34 to 202) |
| Overall HSV-2 infection in seronegative partners | 1.9% | 3.6% | 0.52 (0.27 to 0.99) | 57 (29 to 1051) |
| HSV-1 or HSV-2 infection in seronegative partners | 1.9% | 4.2% | 0.45 (0.24 to 0.84) | 44 (24 to 174) |
| RRR (CI) | ||||
| Genital recurrence in seronegative partners | 39% | 77% | 50% (45 to 55) | 3 (2 to 3) |